The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Improving Cancer Management By Direct Detection With Diffusion-weighted Magnetic Resonance Imaging.
Funder
National Health and Medical Research Council
Funding Amount
$421,549.00
Summary
Despite reliable methods of prostate and breast cancer diagnosis there remains considerable uncertainty as to whether the detected disease will have a significant impact on a patient’s quality of life. This uncertainty is largely due to the inability of current detection methods to show the extent of disease. This project will address this problem by developing new MRI methods that directly measure the microscopic tissue properties that define cancer.
Lymphoedema can occur secondary to treatment for cancer. It is currently diagnosed using methods which do not allow for early diagnosis, allowing significant tissue damage to occur before treatment is commenced. The aim of this research proposal is to improve the detection and diagnosis of lymphoedema so that it can be treated as early as possible, preventing permanent tissue damage and potentially improving prognosis.
Noncoding RNAs As Prognostic Markers And Therapeutic Targets In Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$550,283.00
Summary
Normal human development involves a symphony of genetic changes that control the growth and differentiation of different types of cells during embryogenesis. For many years it has been assumed that most genetic information is transacted by proteins, and that the remaining 98% of the human genome that does not encode proteins was (apart from a limited amount of associated regulatory elements) largely non-functional evolutionary junk. However, this may not be the case. Recent results from our labo ....Normal human development involves a symphony of genetic changes that control the growth and differentiation of different types of cells during embryogenesis. For many years it has been assumed that most genetic information is transacted by proteins, and that the remaining 98% of the human genome that does not encode proteins was (apart from a limited amount of associated regulatory elements) largely non-functional evolutionary junk. However, this may not be the case. Recent results from our laboratory and others have shown that most of our genome and that of other mammals is actually expressed as noncoding RNA, which appears to be developmentally regulated. These RNAs (of which there appear to be tens of thousands, well outnumbering the protein-coding mRNAs) have been referred to as the hidden layer or dark matter of our genome, as they have barely been studied, but appear to play a central role in both normal and abnormal development in humans. There is now increasing evidence that many noncoding RNAs, including small regulatory RNAs called microRNAs, are perturbed in cancer and that these perturbations may be directly involved in, and be an accurate indicator of, cancer state and the direction of cancer progression. If this is true we need to understand the expression and functions of these RNAs in order to develop better diagnostics and perhaps powerful new therapeutics for cancer, based on RNA technology and generic delivery systems. This project will explore the patterns of noncoding RNA expression in normal breast development and in breast cancer, to identify those RNAs that direct or accompany the differentiation of these tissues, and to test the effects of interfering with their expression on these processes. These foundation studies lie at the leading edge of a new understanding of human genetics and cancer, and will provide a platform for future applications in medicine that utilize this information and understanding.Read moreRead less
SNAC2: A Randomised Trial Of Extending Sentinel Node Based Management To Women With Larger Or Multifocal Breast Cancers
Funder
National Health and Medical Research Council
Funding Amount
$1,266,430.00
Summary
SNAC2 extends the work begun in SNAC1, which recruited 1,088 women over 4 years. SNAC1 will determine if sentinel node biopsy causes less arm problems than axillary clearance. The goal of SNAC2 is to establish the risk of local recurrence and long term safety of sentinel node biopsy, especially for women with larger or multiple tumours. SNAC2 is needed to determine whether the smaller operation gives cure rates as good as axillary clearance. If it does, then it will become standard practice.
Quantifying Breast Cancer Over-diagnosis In An Organized Mammography Screening Program
Funder
National Health and Medical Research Council
Funding Amount
$92,314.00
Summary
While breast screening reduces breast cancer deaths by finding cancers earlier, it may also find cancers that would never have required treatment. Currently there is no clear consensus about the level over-diagnosis. This study will examine the extent of over-diagnosis by comparing the breast screening histories of women diagnosed with breast cancer and women who have not had breast cancer. Findings will inform policy on breast screening in Australia.
Risks And Benefits Of Breast Cancer Screening: BreastScreen WA Cohort Study Of Overdiagnosis And Breast Cancer Mortality
Funder
National Health and Medical Research Council
Funding Amount
$201,524.00
Summary
Overdiagnosis is the major downside of screening for breast cancer. This occurs when screening detects cancers that would not have caused symptoms in the woman's lifetime. This study aims to quantify the amount of overdiagnosis that occurs in the Australian breast cancer screening program (BreastScreen)
Comparative Effectiveness Of Breast Tomosynthesis And Mammography In Real-world Population Screening: Evidence To Underpin And Improve Breast Cancer Screening
Funder
National Health and Medical Research Council
Funding Amount
$1,851,430.00
Summary
This research addresses key evidence gaps in breast cancer screening by investigating tomosynthesis (3D mammography) versus standard 2D mammography screening to establish the effectiveness of tomosynthesis in Australia and internationally, including impact on cancers not detected at screening that progress clinically. Large-scale studies will be done in real world screening services including a prospective comparative study planned collaboratively with BreastScreen to guide screening policy.
Genetic Variants, Phenotypic Spectrum And Breast Cancer Risk Associated With Germline Mutations In PALB2: Identifying Female PALB2 Mutation Carriers At The Time Of Diagnosis
Funder
National Health and Medical Research Council
Funding Amount
$45,093.00
Summary
Population studies of female breast cancer (BC) show only a small proportion of familial aspects of BC can be explained by current knowledge of its causes. Women carrying PALB2 mutations who also have a strong family history of BC are of increased risk of BC. Our work will further define the risks and devise criteria to identify women most likely to carry PALB2 mutations. This will help prioritize testing, classify PALB2 variants and provide appropriate clinical management to carriers.
Why Do Some Breast Cancers Present At An Advanced Stage In Women In Australia?
Funder
National Health and Medical Research Council
Funding Amount
$682,950.00
Summary
Each year since 1994, some 10,000 Australian women have been diagnosed with breast cancer and 2,500 have died from it; these deaths have led to loss of some 31,000 years of life before 75 years of age. There is no effective way to prevent breast cancer in most women at risk of it, the only possible intervention is early detection and treatment to reduce the impact of being diagnosed with the disease. The smaller the cancer at treatment, the better the outcome. The national mammographic screening ....Each year since 1994, some 10,000 Australian women have been diagnosed with breast cancer and 2,500 have died from it; these deaths have led to loss of some 31,000 years of life before 75 years of age. There is no effective way to prevent breast cancer in most women at risk of it, the only possible intervention is early detection and treatment to reduce the impact of being diagnosed with the disease. The smaller the cancer at treatment, the better the outcome. The national mammographic screening program, BreastScreen Australia, began in 1991. We expect that screening, through early detection, would reduce the numbers of women who die of breast cancer. Death rates from breast cancer have been falling in Australia since 1994. Despite this program, however, rates of larger breast cancers, more likely to have spread beyond the breast, are not falling. In 1997-98, the woman or her doctor detected nearly half of all breast cancers diagnosed outside of screening by detecting a change in the breast. Given that screening can detect cancers when they are small and that women themselves are also able to detect symptoms that may be small breast cancers and seek medical advice, we must ask why so many cancers are not diagnosed and treated until they are 2cm or larger and threaten life. This project aims to examine reasons in three broad areas: the woman herself, the cancer, and the wider health system, including the medical practitioner to whom symptoms or signs are first presented. Our study aims to understand the factors that contribute the most to the occurrence of larger breast cancers so that public health campaigns can be designed to increase the numbers detected at an early stage.Read moreRead less
Determination Of Diagnostic Molecular Profiles For Intraduct Lesions Of The Breast.
Funder
National Health and Medical Research Council
Funding Amount
$308,400.00
Summary
Breast cancer originates in cells within breast ducts. The introduction of Breast Screening for breast cancer has led to a dramatic increase in the diagnosis of breast cancer which is confined to these ducts and has not spread to surrounding tissue. This is known as 'ductal carcinoma in situ' or DCIS. It is evident that DCIS is variable in its tendency to give rise to more advanced breast cancer. However, currently our ability to predict the potential agressiveness of a particular DCIS is limite ....Breast cancer originates in cells within breast ducts. The introduction of Breast Screening for breast cancer has led to a dramatic increase in the diagnosis of breast cancer which is confined to these ducts and has not spread to surrounding tissue. This is known as 'ductal carcinoma in situ' or DCIS. It is evident that DCIS is variable in its tendency to give rise to more advanced breast cancer. However, currently our ability to predict the potential agressiveness of a particular DCIS is limited. In this research we are proposing to develop new methods for evaluation of DCIS that will more accurately predict clinical behaviour. An important adjunct is to ensure that these methods can be practically applied in a routine diagnostic setting. Achievement of the aims of this project will assist treatment planning for patients diagnosed with DCIS. It will also provide important information about breast cancers diagnosed as a consequence of breast screening.Read moreRead less